• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ambrx Biopharma Inc. (Amendment)

    3/13/23 4:00:18 PM ET
    $AMAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AMAM alert in real time by email
    SC 13G/A 1 schedule13g.htm AMENDMENT NO. 3
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 3)*
     

     
    Ambrx Biopharma Inc.
     
     
    (Name of Issuer)
     

     
    Ordinary Shares, par value $0.0001 per share
     
     
    (Title of Class of Securities)
     

     
    02290A102
     
     
    (CUSIP Number)
     

     
    March 3, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Cormorant Global Healthcare Master Fund, LP

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Cayman Islands

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    42,771,365 shares
     
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    42,771,365 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    42,771,365 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    14.44%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
    PN (Partnership)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Global Healthcare GP, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    42,771,365 shares
     
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    42,771,365 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    42,771,365 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    14.44%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Private Healthcare Fund III, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    9,728,635 shares
     
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    9,728,635 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    9,728,635 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    3.29%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Private Healthcare GP III, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    9,728,635 shares
     
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    9,728,635 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    9,728,635 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    3.29%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Cormorant Asset Management, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    52,500,000 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    52,500,000 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    52,500,000 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    17.73%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Bihua Chen
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    52,500,000 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    52,500,000 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    52,500,000 shares
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    17.73%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    IN (Individual)
     

    Item 1.
    (a)
    Name of Issuer
     
    Ambrx Biopharma Inc.
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    10975 North Torrey Pines Road, La Jolla, CA 92037

    Item 2.
    (a)
    Name of Person Filing
     
    Cormorant Global Healthcare Master Fund, LP
    Cormorant Global Healthcare GP, LLC
    Cormorant Private Healthcare Fund III, LP
    Cormorant Private Healthcare GP III, LLC
    Cormorant Asset Management, LP
    Bihua Chen
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
    200 Clarendon Street, 52nd Floor
    Boston, MA 02116
     
    (c)
    Citizenship
     
     
    Cormorant Global Healthcare Master Fund, LP - Cayman Islands
    Cormorant Global Healthcare GP, LLC - Delaware
    Cormorant Private Healthcare Fund III, LP - Delaware
    Cormorant Private Healthcare GP III, LLC - Delaware
    Cormorant Asset Management, LP - Delaware
    Bihua Chen - United States
     
    (d)
    Title of Class of Securities
     
    Ordinary Shares
     
    (e)
    CUSIP Number
     
    02290A102


    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)
    [ ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)
    [ ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    [ ]
    Insurance Company as defined in Section 3(a)(19) of the Act
    (d)
    [ ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
    [ ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership***
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     
     
    (a)
    Amount Beneficially Owned***
     
     
    The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

     
    (b)
    Percent of Class
       
    The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.

     
    (c)
    Number of shares as to which such person has:
     
       
    (i)
    sole power to vote or to direct the vote



       
    (ii)
    shared power to vote or to direct the vote

       
    (iii)
    sole power to dispose or to direct the disposition of

       
    (iv)
    shared power to dispose or to direct the disposition of
       
    The information set forth in Rows 5 through 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.
      
     
    *** Information presented in this report relates to ordinary shares, including ordinary shares represented by American Depositary Shares, which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”) and Cormorant Private Healthcare Fund III, LP (“Fund III”), as reported herein.  Cormorant Global Healthcare GP, LLC and Cormorant Private Healthcare GP III, LLC serve as the general partners of the Master Fund and Fund III, respectively.  Cormorant Asset Management, LP serves as the investment manager to the Master Fund and Fund III.  Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC and the general partner of Cormorant Asset Management, LP.  Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein.
    The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon (i) a statement in the Issuer’s financial statements attached as Exhibit 99.1 to the Report of Foreign Issuer on Form 6-K filed with the Securities and Exchange Commission on August 29, 2022 that there were 270,328,483 Ordinary Shares outstanding as of June 30, 2022 and (ii) the Reporting Person's knowledge of the issuance on March 3, 2023 of additional American Depository Shares to the Reporting Persons representing 25,796,365 ordinary shares.

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits     Exhibit


    99.1                  Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on July 2, 2021.

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
    March 13, 2023

     
    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
     
    By: Cormorant Global Healthcare GP, LLC
     
    its General Partner
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT GLOBAL HEALTHCARE GP, LLC
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT PRIVATE HEALTHCARE FUND III, LP
     
    By: Cormorant Private Healthcare GP III, LLC
     
    its General Partner
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT PRIVATE HEALTHCARE GP III, LLC
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    CORMORANT ASSET MANAGEMENT, LP
     
    By: Cormorant Asset Management GP, LLC
     
    its General Partner
       
     
    By: /s/ Bihua Chen
     
    Bihua Chen, Managing Member
       
     
    /s/ Bihua Chen
     
    Bihua Chen

     
    Get the next $AMAM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMAM

    DatePrice TargetRatingAnalyst
    9/25/2023$15.00Mkt Outperform
    JMP Securities
    9/12/2023$26.00Buy
    BTIG Research
    7/31/2023$29.00Outperform
    RBC Capital Mkts
    6/14/2023$26.00Buy
    B. Riley Securities
    6/2/2023$30.00Outperform
    Oppenheimer
    5/19/2023$25.00Overweight
    Cantor Fitzgerald
    4/7/2022$16.00Outperform
    Robert W. Baird
    2/28/2022$6.00Neutral
    Goldman Sachs
    More analyst ratings

    $AMAM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ambrx Shareholders Approve Acquisition by Johnson & Johnson

      SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders. As previously announced, under the terms of the transaction, Ambrx shareholders will receive $28.00 per share in cash in connection with the closing of the transaction. Daniel J. O'Connor, Chief Executive Officer of Ambrx, said, "We want to thank our shareholders for their strong support of this transaction. With a steadfast focus on protein engineering innovation and some of the best ADC talent in t

      3/6/24 1:20:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Announces Sale to Johnson & Johnson

      SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ:AMAM), today announced that it has entered into a definitive agreement pursuant to which Johnson & Johnson will acquire all of the outstanding shares of Ambrx for $28.00 per share in cash, representing an approximately 105% premium to Ambrx's closing stock price on January 5, 2024, for a total equity value of approximately $2.0 billion. "We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unmet needs," said Daniel J. O'Connor, Chief Executive Officer of Ambrx. "With our deep and unique knowledge of precision engineering of protein ther

      1/8/24 7:35:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Hermans Kate

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 7:23:35 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Loesberg Janet

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 7:19:43 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • O'Connor Daniel J. returned 48,202 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Ambrx Biopharma, Inc. (0001990550) (Issuer)

      3/7/24 5:46:49 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Leadership Updates

    Live Leadership Updates

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs

      SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. ("Ambrx" or the "Company") (NASDAQ:AMAM), today announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish will be responsible for overseeing and designing the Company's global regulatory strategy and will report to the Company's President and Chief Executive Officer, Daniel J. O'Connor. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive experience in oncology drug development ranging from pre-clinical to commercial products in many fields, including prostate and breast cancer. She has held senior regulatory leadership positions at Celgene, Merck and Kite Phar

      8/1/23 8:30:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Appoints Jared Kelly as General Counsel

      SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ:AMAM), today announced the appointment of Jared Kelly as Senior Vice President, General Counsel and Corporate Secretary. After practicing for more than ten years at large corporate law firms, Mr. Kelly brings his extensive experience advising public companies on corporate governance, financing transactions and mergers and acquisitions to Ambrx. He will be responsible for developing and overseeing the legal strategy of the Company and for providing legal guidance to the Company's board of directors, executive management team and other business units. Mr. Kelly is an experienced public company lawyer who

      6/5/23 8:30:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Ambrx Biopharma with a new price target

      JMP Securities initiated coverage of Ambrx Biopharma with a rating of Mkt Outperform and set a new price target of $15.00

      9/25/23 7:12:57 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BTIG Research initiated coverage on Ambrx Biopharma with a new price target

      BTIG Research initiated coverage of Ambrx Biopharma with a rating of Buy and set a new price target of $26.00

      9/12/23 7:13:06 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • RBC Capital Mkts initiated coverage on Ambrx Biopharma with a new price target

      RBC Capital Mkts initiated coverage of Ambrx Biopharma with a rating of Outperform and set a new price target of $29.00

      7/31/23 7:17:15 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    SEC Filings

    See more
    • SEC Form 15-12G filed by Ambrx Biopharma Inc.

      15-12G - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/18/24 2:45:48 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma Inc. filed SEC Form 8-K: Leadership Update

      8-K - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/12/24 4:55:02 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Ambrx Biopharma Inc.

      EFFECT - Ambrx Biopharma, Inc. (0001990550) (Filer)

      3/11/24 12:15:20 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ambrx Biopharma Inc. (Amendment)

      SC 13G/A - Ambrx Biopharma Cayman, Inc. (0001836056) (Subject)

      2/9/24 5:08:30 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ambrx Biopharma Inc.

      SC 13G - Ambrx Biopharma Inc. (0001836056) (Subject)

      10/10/23 11:35:22 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Ambrx Biopharma Inc.

      SC 13G - Ambrx Biopharma Inc. (0001836056) (Subject)

      9/25/23 5:24:50 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Financials

    Live finance-specific insights

    See more
    • Ambrx to Commence Trading on Nasdaq

      Company to Transfer Stock Exchange Listing from NYSE to Nasdaq Ticker symbol will remain "AMAM" Ambrx Biopharma Inc. (NYSE: AMAM) ("Ambrx" or "the Company") today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx's American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker symbol "AMAM". "The listing of our stock on the Nasdaq represents a significant milestone in our growth as a publicly-traded company and is an important step that will help facilitate our mission to di

      3/6/23 9:00:00 AM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma Inc. Announces Strategic Reprioritization and Provides Corporate Update

      - Company now focused on earlier stage engineered antibody drugs for cancer therapies, including new lead asset ARX517 – - Revised focus and projected cost-reductions expected to extend cash runway into 2025 – - Ambrx to host a conference call today at 5:00 p.m. EST / 2:00 p.m. PST - SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced a strategic reprioritization of its pipeline and provided a corporate update. The strategic assessment considered the company's cash runway, pipeline near term v

      10/18/22 4:05:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Biopharma to Host Corporate Update Conference Call

      SAN DIEGO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE:AMAM), a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics (EPBs), today announced the company will host a corporate update conference call and live webcast on October 18, 2022 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time, to discuss the company's strategic review of its development pipeline. Individuals interested in listening to the conference call may do so by registering via the webcast link in the investor relations section of the company's website at: www.ambrx.com. To access the call by phone, please use the reg

      10/11/22 4:05:00 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AMAM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cormorant Asset Management, Lp bought $19,625,601 worth of Ordinary Shares (2,152,738 units at $9.12)

      4 - Ambrx Biopharma Inc. (0001836056) (Issuer)

      9/19/23 4:49:06 PM ET
      $AMAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care